A Cochrane review [Abstract] 1 included 108 studies (18 placebo-controlled and 90 before-and-after) with a total of 19 596 subjects. Manufacturer-recommended rosuvastatin doses of 10 to 40 mg/day caused LDL-cholesterol decreases of 46% to 55% (table T1).
| Intervention | Participants (studies) | Percent change from baseline (95% CI) |
|---|---|---|
| Rosuvastatin 2.5 mg/day | 450 (11) | -39.1% (-40.6 to -37.6%) |
| Rosuvastatin 5 mg/day | 2 602 (25) | -41.3% (-42.0 to -40.7%) |
| Rosuvastatin 10 mg/day | 9 855 (74) | -45.6% (-46.0 to -45.3%) |
| Rosuvastatin 20 mg/day | 3 675 (28) | -49.9% (-50.4 to -49.4%) |
| Rosuvastatin 40 mg/day | 3 512 (18) | -54.9% (-55.4 to -54.4%) |
Log dose-response data over doses of 1 to 80 mg, revealed strong linear dose-related effects on blood total cholesterol, LDL-cholesterol and non-HDL-cholesterol. When compared to atorvastatin, rosuvastatin was about three-fold more potent at reducing LDL-cholesterol. There was no dose-related effect of rosuvastatin on blood HDL-cholesterol, but overall, rosuvastatin increased HDL by 7%.
Withdrawals due to adverse effects were not statistically different between rosuvastatin and placebo in 10 of 18 of these short-term trials. However, this review did not provide a good estimate of the incidence of harms associated with rosuvastatin because of the short duration of the trials and the lack of reporting of adverse effects in 44% of the placebo-controlled trials.
Date of latest search:
Primary/Secondary Keywords